Research News

Rucaparib Receives Breakthrough Therapy Designation from FDA

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer…

Read on

OCRF Now Accepting Applications for 2016 Research Grants

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015…

Read on

Microenvironment Regulates Tumor Suppressor miRNA

(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells…

Read on

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1…

Read on

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer…

Read on

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer…

Read on

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival…

Read on

OCRF Research Finds New Therapeutic Strategy for Ovarian Cancer

(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease…

Read on

New Tool Could Speed Development of Ovarian Cancer Drugs

(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds…

Read on

Meet OCRF’s 2015 Grantees

(February 11, 2015) Ovarian Cancer Research Fund has announced that $6.1 million has been awarded in scientific research grants for ovarian cancer…

Read on

SGI-110 is an Ovarian Cancer Chemosensitizer

(February 4, 2014)  In research published last October in Clinical Cancer Research, a team of OCRF-funded investigators showed that a novel therapy can resentisize ovarian cancer to chemotherapy.  The work was led by Dr…

Read on

OCRF Research Identifies Six New Susceptibility Loci for Ovarian Cancer

(Feb. 3, 2015) An international study using data from the OCRF-funded Ovarian Cancer Association Consortium has found six new gene regions which increase a woman’s risk of ovarian cancer…

Read on